Literature DB >> 20502172

Drug-induced acute liver failure and gastrointestinal complications.

Ishaq Lat1, David R Foster, Brian Erstad.   

Abstract

The objective of this article is to describe adverse drug events related to the liver and gastrointestinal tract in critically ill patients. PubMed and other resources were used to identify information related to drug-induced acute liver failure, gastrointestinal hypomotility, constipation, diarrhea, gastrointestinal bleeding, and pancreatitis in critically ill patients. This information was reviewed, and data regarding pathophysiology, common drug causes, and guidelines for prevention and management were collected and summarized. In cases in which data in critically ill patients were unavailable, data were extrapolated from other patient populations. Drug-induced acute liver failure can be caused by many drugs routinely used in the intensive care unit and may be associated with significant morbidity and mortality. Drug-related hypomotility and constipation and drug-related diarrhea are reported with many drugs, and these are common adverse drug events in critically ill patients that can substantially complicate the care of these patients. Drug-induced gastrointestinal bleeding and drug-induced pancreatitis occur less frequently, can range in disease severity, and can be associated with morbidity and mortality. Many drugs used in critically ill patients are associated with adverse drug events related to the liver and gastrointestinal tract. Critical care clinicians should be aware of common drug causes of drug-induced acute liver failure, gastrointestinal hypomotility, constipation, diarrhea, gastrointestinal bleeding, and pancreatitis, and should be familiar with the prevention and management of these diverse conditions.

Entities:  

Mesh:

Year:  2010        PMID: 20502172     DOI: 10.1097/CCM.0b013e3181de0db2

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  4 in total

Review 1.  Cholestatic liver (dys)function during sepsis and other critical illnesses.

Authors:  Marc Jenniskens; Lies Langouche; Yoo-Mee Vanwijngaerden; Dieter Mesotten; Greet Van den Berghe
Journal:  Intensive Care Med       Date:  2015-09-21       Impact factor: 17.440

Review 2.  Advances in the management of acute liver failure.

Authors:  Da-Wei Wang; Yi-Mei Yin; Yong-Ming Yao
Journal:  World J Gastroenterol       Date:  2013-11-07       Impact factor: 5.742

3.  The effect of silymarin on liver enzymes and antioxidant status in trauma patients in the intensive care unit: a randomized double blinded placebo-controlled clinical trial.

Authors:  Ehsan Mirzaei; Golnar Sabetian; Mansoor Masjedi; Reza Heidari; Mahtabalsadat Mirjalili; Amirreza Dehghanian; Afsaneh Vazin
Journal:  Clin Exp Hepatol       Date:  2021-06-22

4.  Translational potential of a mouse in vitro bioassay in predicting gastrointestinal adverse drug reactions in Phase I clinical trials.

Authors:  C Keating; L Ewart; L Grundy; J P Valentin; D Grundy
Journal:  Neurogastroenterol Motil       Date:  2014-05-11       Impact factor: 3.598

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.